Estimated Cost-effectiveness of Genetic Testing in Siblings of Newborns With Cancer Susceptibility Gene Variants

Newborn population-based genetic screening may reduce pediatric cancer deaths and could be cost-effective. Testing siblings of newborns with variants (ie, cascade testing) could further improve population health. Economic studies of cascade testing have focused on adults, although evidence suggests that cost-effectiveness improves for some cancer syndromes when surveillance is initiated in younger individuals.³ Our objective was to estimate the benefits and costs of cascade testing of siblings of newborns with cancer susceptibility gene variants.